Compare
Reviva Pharmaceuticals Holdings, Inc. vs Anixa Biosciences Inc vs Aditxt, Inc. vs Cingulate Inc.
| Latest fiscal year | Reviva Pharmaceuticals Holdings, Inc. RVPH | Anixa Biosciences Inc ANIX | Aditxt, Inc. ADTX | Cingulate Inc. CING |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-10-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $3.2K | n/a |
| Revenue growth (YoY) | n/a | n/a | -97.6% | n/a |
| Gross margin | n/a | n/a | 8.4% | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$19.86M | -$10.93M | -$43.10M | -$22.45M |
| EPS (Diluted) | n/a | -$0.34 | -$1153.83 | -$4.44 |
| Operating cash flow | -$24.59M | -$7.17M | -$25.69M | -$17.25M |
| Free cash flow | n/a | n/a | -$25.70M | -$17.41M |
| Cash & equivalents | $14.44M | $1.24M | n/a | $10.95M |
| Total assets | $15.92M | $16.08M | $16.52M | $15.07M |
| Total liabilities | $7.28M | $2.13M | $12.56M | $12.56M |
| Shareholders' equity | $8.65M | $15.16M | $5.61M | $2.51M |
| Return on year-end equity | -229.7% | -72.1% | -768.3% | -894.8% |
| Shares outstanding | 5.87M | 33.01M | 411.5K | 7.25M |
Revenue, most recent five fiscal years
| Fiscal year | Reviva Pharmaceuticals Holdings, Inc. | Anixa Biosciences Inc | Aditxt, Inc. | Cingulate Inc. |
|---|---|---|---|---|
| Latest | n/a | $210.0K Ended 2024-10-31 | $3.2K Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $210.0K Ended 2023-10-31 | $134.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $645.2K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $512.0K Ended 2021-10-31 | $933.7K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $105.0K Ended 2021-12-31 | n/a |